top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIgE/hFCER1A mice
Strain Name
C57BL/6N-Ighetm1(IGHE)BcgenFcer1atm1(FCER1A)Bcgen/Bcgen
Common Name  B-hIgE/hFCER1A mice
Background C57BL/6N Catalog number 111891
Related Genes 
IGHE, IgE; FCER1A, FCE1A, FcERI, Fc fragment of IgE receptor Ia

Protein expression analysis in serum


from clipboard

Strain specific IgE expression analysis in wild-type C57BL/6JNifdc mice and homozygous humanized B-hIgE/hFCER1A mice by ELISA. Serum was collected from wild-type C57BL/6JNifdc mice (+/+) and homozygous B-hIgE/hFCER1A mice (H/H) (male, 8 weeks old, n=3). Expression level of human IgE was analyzed by ELISA. Human IgE was exclusively detectable in homozygous B-hIgE/hFCER1A mice. Values are expressed as mean ± SEM. 

Protein expression analysis in basophils 

from clipboard


Strain specific IgE expression analysis in homozygous B-hIgE/hFCER1A mice by flow cytometry. Basophilic granulocytes of the bone marrow were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hIgE/hFCER1A mice (H/H;H/H) stimulated with LPS in vivo, and analyzed by flow cytometry with species-specific anti-IgE antibody. Mouse IgE was detectable in WT mice (+/+). Human IgE was exclusively detectable in homozygous B-hIgE/hFCER1A mice (H/H;H/H) but not in WT mice (+/+).

from clipboard


Strain specific FCER1A expression analysis in homozygous B-hIgE/hFCER1A mice by flow cytometry. Basophilic granulocytes of the bone marrow were collected from wild type (WT) mice (+/+) and homozygous B-hIgE/hFCER1A mice (H/H;H/H), and analyzed by flow cytometry with species-specific anti-FCER1A antibody. Mouse FCER1A was detectable in WT mice (+/+). Human FCER1A was exclusively detectable in homozygous B-hIgE/hFCER1A mice (H/H;H/H) but not in WT mice (+/+).


Omalizumab alleviated OVA induced active systemic anaphylaxis (ASA) in B-hIgE/hFCER1A mice


from clipboard


Effects of Omalizumab on OVA induced ASA. B-hIgE/hFCER1A mice (H/H; H/H) received OVA/Al(OH)3 immunization on day 0, and challenge with OVA on day 14. Omalizumab (in house) was injected 3 hour before challenge on day 14. (A) The body temperature of the mice was recorded from 0 to 90 minutes after the challenge. (B) An increasing trend was produced by Omalizumab (in house) in the ASA model. It can be seen that Omalizumab (in house) has an inhibitory effect on the decrease in body temperature caused by ASA modeling in B-hIgE/hFCER1A mice (H/H; H/H).